MedDRA preferred term · overactive thyroid

Hyperthyroidism: adverse event reports recording this term

14,220 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

14,220
reports recording the term: 0.1% of all reports; 1,025
reports, 12 months to June 2026: 957 in the 12 months before; 93%
marked serious by the reporter: 57.4% across all reports; 5.1%
record death among outcomes, as reported: 9.1% across all reports

14,220 reports in FDA's adverse event database record the MedDRA term "Hyperthyroidism" (in plain words, overactive thyroid): 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

1,025 reports recorded it in the 12 months to June 2026, close to the 957 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 93% are marked serious, 5.1% include death among the outcomes and 38% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Amiodarone, Novothyrox and Nivolumab. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Amiodarone	—	999	6%
Novothyrox	—	704	6.7%
Nivolumab	Programmed death Receptor-1 blocking antibody	603	1.3%
Keytruda	Programmed death Receptor-1 blocking antibody	531	0.8%
Carboplatin	Platinum-based drug	495	0.5%
Levothyroxine	—	461	2.9%
Opdivo	Programmed death Receptor-1 blocking antibody	387	0.8%
Atezolizumab	Programmed death Receptor-1 blocking antibody	378	1.9%
Pembrolizumab	Programmed death Receptor-1 blocking antibody	348	1.1%
Amiodarone hcl	—	331	6%
Amiodarone hydrochloride	Antiarrhythmic	331	6.3%
Ipilimumab	CTLA-4-directed blocking antibody	329	1.7%
Synthroid	l-Thyroxine	312	1.2%
Levothyroxine sodium	l-Thyroxine	308	2.1%
Cordarone	—	259	3.7%
Yervoy	CTLA-4-directed blocking antibody	257	1.2%
Paclitaxel	Microtubule inhibitor	242	0.3%
Humira	—	237	0%
Prednisone	Corticosteroid	224	0.1%
Bevacizumab	Vascular endothelial growth factor inhibitor	196	0.4%
Methimazole	Thyroid hormone synthesis inhibitor	182	7.2%
Euthyrox	l-Thyroxine	163	4.5%
Pemetrexed	Folate analog metabolic inhibitor	160	0.9%
Furosemide	Loop diuretic	143	0.3%
Alemtuzumab	CD52-directed cytolytic antibody	137	1.6%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Programmed death Receptor-1 blocking antibody	2,350	1%	1%
Kinase inhibitor	933	0.1%	0%
l-Thyroxine	915	1.8%	2.1%
Platinum-based drug	637	0.3%	0.2%
CTLA-4-directed blocking antibody	604	1.3%	0.9%
Corticosteroid	561	0.1%	0%
Antiarrhythmic	414	1.3%	0.1%
beta-Adrenergic blocker	324	0.2%	0%
Atypical antipsychotic	272	0%	0%
Microtubule inhibitor	269	0.2%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.1%19

2 to 110.4%62

12 to 172%282

18 to 4414.5%2,065

45 to 6427.8%3,948

65 to 7415.2%2,159

75 and over9.7%1,385

Age not given30.2%4,300

Patient sex

Female57.2%8,134

Male32.5%4,626

Not given10.3%1,460

Grey bar: all 20,646,523 reports in the database. 34.9% of these reports give the United States as the country.

Questions about "Hyperthyroidism"

What does "Hyperthyroidism" mean in an adverse event report?

In plain language: overactive thyroid. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record hyperthyroidism?

14,220 reports through June 2026 (0.1% of all reports), 1,025 of them in the latest 12 months.

Which drugs appear most often in these reports?

Amiodarone (999), Novothyrox (704), Nivolumab (603), Keytruda (531) and Carboplatin (495). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.